PF-ILD is a suspected infectious disease in the field of respiratory digestive and endocrine disorders, with complex clinical outcomes that often involve multi-system congestion. Early identification and standardized diagnosis are critical to improving prognosis. The diagnosis of this disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD-associated zincamide. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.